|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic phosphopeptide derived from human DARPP-32 around the phosphorylation site of Thr34 (R-P-TP-P-A)|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.4, with 150mM NaCl, 50% glycerol|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Dopaminergic signaling pathways, which are essential for multiple brain functions, are abnormal in several neurological disorders, such as schizophrenia, Parkinson's disease and drug abuse. DARPP-32 (for dopamine and adenosine 3',5'-monophosphate-regulated phosphoprotein of 32 kDa) is abundant in neurons that receive dopaminergic input. Activation of PKA and the consequent phosphorylation of DARPP-32 on threonine occurs in response to dopamine acting upon D1-like receptors. Dopamine interaction with D2-like receptors results in the inhibition of PKA activation, the activation of protein phosphatase 2B and the consequent dephosphorylation of DARPP-32. Neurotransmitters other than dopamine may also be able to stimulate the phosphorylation or dephosphorylation of DARPP-32. Phosphorylated DARPP-32 is a potent inhibitor of PP-1.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.